Effects to obliterative bronchiolitis by blocking CD40-CD40L pathway in the mouse lung transplantation

doi:10.3969/j.issn.1006-7795.2018.02.019

Abstract

Abstract: Objective Our research focus on the effects to obliterative bronchiolitis (OB) by blocking CD40-CD40L pathway with anti-mCD40L on allografts in mouse orthotopic lung transplantation model, and comparing with traditional immunosuppressive agents-cyclosporine/methylprednisolone (C/M) to explore new clinical treatment methods. Methods Murine orthotopic lung transplantation was performed in wild type C57BL/6 mice using Balb/c donors. At day 10, histopathologic characteristics were assessed by hematoxylin-eosin (HE) staining, Masson staining and neutrophil staining with antimyeloperoxidase; real-time polymerase chain reaction (RT-PCR) was performed for interleukin-17A (IL-17A) expressions. Results Donor lung of recipients were harvested at 10 days after transplantation. Groups with treatment of anti-mCD40L and cyclosporine/methylprednisolone showed an enlargement appearance compared with allograft group. Pathology results demonstrated that administration of anti-mCD40L can better improve rejection injury and OB compared with cyclosporine/methylprednisolone treatment group (P<0.05). Furthermore, administration of anti-mCD40L significantly reduced transcription levels of IL-17A in grafts(P<0.01). Conclusion This findings demonstrated that by blocking CD40-CD40L pathway with anti-mCD40L can better alleviate transplant rejection and OB mediated by IL-17A in mouse lung transplantation.

Key words: mouse left orthotopic lung transplantation, anti-mCD40L, cyclosporine/methylprednisolone, obliterative bronchiolitis(OB)

CLC Number:

R392.4

Chen Rongjuan, Chen Qirui, Xu Jiangnan, Ding Yuezhong. Effects to obliterative bronchiolitis by blocking CD40-CD40L pathway in the mouse lung transplantation[J]. Journal of Capital Medical University, 2018, 39(2): 258-264.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2018.02.019

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2018/V39/I2/258

References

[1] Wilkes D S, Egan T M, Reynolds H Y. Lung transplantation:opportunities for research and clinical advancement[J]. Am J Respir Crit Care Med, 2005,172(8):944-955.
[2] Christie J D, Edwards L B, Kucheryavaya A Y, et al. The registry of the international society for heart and lung transplantation:twenty-seventh official adult lung and heart-lung transplant report-2010[J]. J Heart Lung Transplant, 2010,29(10):1104-1118.
[3] Belperio J A, Weigt S S, Fishbein M C, et al. Chronic lung allograft rejection:mechanisms and therapy[J]. Proc Am Thrac Soc, 2009, 6(1):108-121.
[4] Chen Q R, Wang L F, Xia S S, et al. Role of interleukin-17A in early graft rejection after orthotopic lung transplantation in mice[J]. J Thorac Dis, 2016, 8(6):1069-1079.
[5] Shilling R A, Wilkes D S. Role of Th17 cells and IL-17 in lung transplant rejection[J]. Semin Inmmunopathol,2011, 33(2):129-134.
[6] Mcdyer J F, Goletz T J, Thomas E, et al. CD40 ligand/CD40 stimulation regulates the production of IFN-gamma from human peripheral blood mononuclear cells in an IL-12-and/or CD28-dependent manner[J]. J Immunol, 1998, 160(4):1701-1707.
[7] Ensminger S M, Witzke O, Spriewald B M, et al. CD8⁺ T cells contribute to the development of transplant arteriosclerosis despite CD154 blockade[J]. Transplantation, 2000, 69(12):2609-2612.
[8] Guo Z, Meng L, Kim O, et al. CD8 T cell-mediated rejection of intestinal allografts is resistant to inhibition of the CD40/CD154 costimulatory pathway[J]. Transplantation, 2001, 71(9):1351-1354.
[9] Jones N D, Van M A, Hara M, et al. CD40^-CD40 ligand-independent activation of CD8⁺ T cells can trigger allograft rejection[J]. J Immunol, 2000, 165(2):1111-1118.
[10] Dodd-o J M, Lendermon E A, Miller H L, et al. CD154 blockade abrogates allospecific responses and enhances CD4⁺ regulatory T cells in mouse orthotopic lung transplant[J]. Am J Transplant, 2011, 11(9):1815-1824.
[11] Hübner R H, Gitter W, El Mokhtari N E, et al. Standardized quantification of pulmonary fibrosis in histological samples[J]. Biotechniques, 2008, 44(4):507-511.
[12] Lin X, Li W, Lai J, et al. Five-year update on the mouse model of orthotopic lung transplantation:Scientific uses, tricks of the trade, and tips for success[J]. J Thorac Dis, 2012, 4(3):247-258.
[13] Jungraithmayr W, Weder W. The technique of orthotopic mouse lung transplantation as a movie-improved learning by visualization[J]. Am J Transplant, 2012, 12(6):1624-1626.
[14] Krupnick A S, Lin X, Li W, et al. Orthotopic mouse lung transplantation as experimental methodology to study transplant and tumor biology[J]. Nat Protoc, 2009, 4(1):86-93.
[15] Paantjens A W, Vande Graaf E A, Kwakkel-van Erp J M, et al. Lung transplantation affects expression of the chemokine receptor type 4 on specific T cell subsets[J]. Clin Exp Immunol, 2011, 166(1):103-109.
[16] Lunsford K E, Jayanshankar K, Eiring A M, et al. Alloreactive (CD4-independent)CD8⁺ T cells jeopardize long-term survival of intrahepatic islet allografts[J]. Am J Transplant, 2008, 8(6):1113-1128.
[17] Trambley J, Bingaman A W, Lin A, et al. Asialo GM1⁺ CD8⁺ T cells play a critical role in costimulation blockade-resistant allograft rejection[J]. J Clin Invest, 1999, 104(12):1715-1722.
[18] Henn V, Steinbach S, Büchner K, et al. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40[J]. Blood, 2001, 98(4):1047-1054.
[19] Quezada S A, Jarvinen L Z, Lind E F, et al. CD40/CD154 interactions at the interface of tolerance and immunity[J]. Annu Rev Immunol, 2004, 22(1):307-328.
[20] Bucher P, Gang M, Morel P, et al. Transplantation of discordant xenogeneic islets using repeated therapy with anti-CD154[J]. Transplantation, 2005, 79(11):1545-1552.
[21] Kalache S, Lakhani P, Heeger P S. Effects of preexisting autoimmunity on heart graft prolongation after donor-specific transfusion and anti-CD154[J]. Transplantation, 2014, 97(1):12-19.
[22] Zhang T, Pierson R N 3rd, Azimzadeh A M. Update on CD40 and CD154 blockade in transplant models[J]. Immunotherapy, 2015, 7(8):899-911.
[23] Yamada Y, Vandermeulen E, Heigl T, et al. The role of recipient derived interleukin-17A in a murine orthotopic lung transpl model of restrictive chronic lung allograft dysfunction[J]. Transpl Immunol, 2016, 39:10-17.
[24] Fan L, Benson H L, Vittal R, et al. Neutralizing IL-17 prevents obliterative bronchiolitis in murine orthotopic lung transplantation[J]. Am J Transplant, 2011, 11(5):911-922.
[25] Gupta P K, Wagner S R, Wu Q, et al. IL-17A blockade attenuates obliterative bronchiolitis and IFNγ cellular immune response in lung allografts[J]. Am J Respir Cell Mol Biol, 201756(6):708-715.
[26] Vanaudenaerde B M, De Vleeschauwer S I, Vos R, et al. The role of the IL23/IL17 axis in pronchiolitis obliterans syndrome after lung transplantation[J]. Am J Transplant, 2008, 8(9):1911-1920.
[27] Burlingham W J, Love R B, Jankowska-Gan E, et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants[J]. J Clin Invest, 2007, 117(11):3498-3506.
[28] Zheng L, Walters E H, Ward C, et al. Airway neutrophilia in stable and bronchiolitis obliterans syndrome patients following lung transplantation[J]. Thorax, 2000, 55(1):53-59.
[29] Kawaguchi M, Onuchic L F, Li X D, et al. Identification of a novel cytokine, ML-1, and its expression in subjects with asthma[J]. J Immunol, 2001, 167(8):4430-4435.
[30] Bonville C A, Percopo C M, Dyer K D, et al. Interferon-gamma coordinates CCL3-mediated neutrophil recruitment in vivo[J]. BMC immunol, 2009, 10(1):14.
[31] Govan J R, Deretic V. Microbial pathogenesis in cystic fibrosis:mucoid pseudomonas aeruginosa and burkholderia cepacia[J]. Microbiol Rev, 1996, 60(3):539-574.